Skip to main content

Advertisement

Table 3 Multivariate analysis for independent factors associated with response rate, progression free survival and overall survivals in 355 cervical cancer patients (only significant results were shown)

From: Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy

Variables Overall response rate Progression free survival Overall survival
OR (95% CI) P HR (95% CI) P HR (95% CI) P
Body mass index, kg/m2
 < 18.5 2.064 (1.267–3.364) 0.004   
 18.5–24.9 2.165 (1.051–4.461) 0.036     
 ≥ 25 reference      
Histopathology
 Non-SCC   reference   reference  
 SCC    1.334 (1.060–1.678) 0.014 1.533 (1.034–2.272) 0.034
Disease sites before chemotherapy initiation
 Locoregional   reference   reference  
 Distant metastasis    1.315 (1.042–1.660) 0.021 2.008 (1.319–3.056) 0.001
Neutrophil count, /mm3
 ≤ 7000    reference  
 > 7000      1.821 (1.139–2.910) 0.012
NLR
 < 3.6 reference   reference   reference  
 ≥ 3.6 1.642 (1.048–2.572) 0.030 1.676 (1.334–2.107) < 0.001 2.544 (1.672–3.870) < 0.001
Platelet count, /mm3
 ≤ 400,000   reference   reference  
 > 400,000    1.334 (1.060–1.678) 0.014 1.633 (1.078–2.474) 0.021
  1. CI confidence interval, HR hazard ratio, NLR neutrophil-lymphocyte ratio, OR odds ratio, SCC squamous cell carcinoma